On April 3, a study published in the journal Nature, scientists from Stanford University found that blocking the activity of protein CD22 with an antibody can improve cognitive behavior in aging mice. Dr. Tony Wyss-Coray, a professor of neuroscience, led the research. Dr. Wyss-Coray has been working for years… Continue Reading Is it difficult to develop Alzheimer’s disease “new drug”? This target may be a savior
In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal. Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named… Continue Reading Lilly will gamble on Alzheimer’s disease and collaborate to develop a preclinical Tau protein-targeted drug for $2 billion.
The idea of reducing the risk of Alzheimer’s disease through lifestyle changes has been questioned in the past, but there is now more and more evidence that this approach is feasible. This article is organized in a special report from Nature. Figure: The Mediterranean diet rich in olive oil may… Continue Reading How to prevent Alzheimer’s disease?
Alzheimer’s disease (AD) has been associated with many infectious agents such as viruses, bacteria, and fungi. However, this area has been excluded from mainstream research. There are many reasons for this. As early as sixty years ago, Sjogrend et al. speculated that microbes are related to the pathological process… Continue Reading Can the virus induce Alzheimer’s disease?
The Colombian writer Marquez wrote several paragraphs in his “One Hundred Years of Solitude”: José Alkateo Buendia realized that insomnia had invaded the town and he called parents to tell them what they knew about amnesia. The people decided to take measures to prevent the disaster from expanding to… Continue Reading The mystery of Alzheimer’s disease
On June 12, Lilly/AstraZeneca announced the termination of the global phase III project for the treatment of Alzheimer’s disease with lanabecestat (oral BACE inhibitor). Lilly and AstraZeneca reached an alliance to develop lanabecestat in 2014. Lilly is mainly responsible for clinical development work. AstraZeneca is mainly responsible for pharmaceutical production.… Continue Reading Another phase III drug for Alzheimer’s disease failed! BACE target failure rate exceeds 80%
Alzheimer’s disease may have originated from some unknown type of diabetes! This rather shocking hypothesis is expected to open up new avenues for the treatment of Alzheimer’s disease and even to find preventive measures. “Alzheimer’s disease is diabetes in the brain.” This remark first aroused great repercussions in the field… Continue Reading Is Alzheimer’s disease called “Type III” diabetes?
Forgetting, one of the most sad diseases Alzheimer’s disease is a condition that makes countless people to feel fear and power from deep inside. Perhaps people think that this is only an unfortunate disease that the old people will have. But in fact, the ageing of the human brain starts… Continue Reading A drop of blood can predict whether can you escape Alzheimer’s disease
With the release of successful clinical data, many biopharmaceutical and biotech company “stories” have performed perfectly in 2017. Many companies have achieved milestone results, such as the first genetically modified living cell. Drugs (CAR-T therapy) received FDA approval. Of course, there are some painful new drug projects. For example, a… Continue Reading The most anticipated 15 key clinical research data in 2018
Dilemma More than 10 million people worldwide suffer from cancer each year. Although the incidence of Alzheimer’s disease is not as good as that of cancer, there are more than 40 million patients worldwide. One disease causes the patient to die from the malignant proliferation of cells, while the other… Continue Reading Alzheimer’s disease drug development difficulties (7)